While US government sits out this year, EU officials are on the ground in San Francisco leading the conversations on today’s top cybersecurity challenges.
Multimodal AI for Alzheimer Disease Diagnosis: Systematic Review of Datasets, Models, and Modalities
Background: Early detection of Alzheimer disease (AD) is essential for timely intervention; yet, diagnostic performance varies widely across modalities and datasets. Recent multimodal artificial intelligence (AI) models have made significant progress, but the evidence base remains fragmented due to heterogeneous datasets, modeling frameworks, and reporting quality. Objective: This systematic review aimed to analyze studies on […]
Suicidal Thoughts and Behaviors Among Chinese Adolescents in Relation to Negative Life Events, Internet Addiction, and Sexual Abuse: Cross-Sectional Study
Background: Increasing suicidal thoughts and behaviors (STB) among adolescents raise social concerns and have a well-recognized association with sexual abuse (SA). However, research regarding the mechanisms explaining the association between SA and STB remains limited. Objective: This study aims to examine the chained mediating effects of negative life events (NLE) and internet addiction (IA) between […]
Willingness to Share Internet Use Data for Research on Early Disease Detection: Cross-Sectional Survey
Background: Preliminary research has suggested that internet use data could offer digital signals of early disease and has the potential to facilitate early detection and improve patient outcomes. However, there are significant challenges in linking individual-level internet use data with health outcomes. One key aspect is that the public might not be willing to share […]
Determinants of the Uptake and Frequency of Use of a Web Portal Digital Health Intervention in Patients With Type 2 Diabetes and/or Coronary Heart Disease: Secondary Analysis of a Randomized Controlled Trial
Background: The targeted application and design of digital health interventions (DHIs) require an understanding of usage determinants. Usage includes uptake (initial use) and frequency (extent of use), but it is unclear whether both components are driven by the same determinants. Objective: This study aimed to examine the determinants of uptake and frequency of use and […]
Improving Retrieval Augmented Generation for Health Care by Fine-Tuning Clinical Embedding Models: Development and Evaluation Study
Background: Embedding models are critical components of Retrieval Augmented Generation (RAG) systems for retrieving and searching unstructured medical data. However, existing models are predominantly trained on publicly available English datasets, limiting their effectiveness in non-English health care settings. More importantly, these models lack training on real-world clinical documents, leading to inaccurate context retrieval when integrated […]
FDA gives Denali accelerated approval for rare disease drug
The FDA granted accelerated approval to Denali Therapeutics’ rare disease drug Avlayah, bucking a recent trend of rejections in the space that has put the agency under political pressure. Avlayah, whose generic name is tividenofusp …
Anavex sinks after pulling Alzheimer’s filing in EU
Shares in Anavex Life Sciences lost more than a third of their value today after the company abandoned an EU filing for its Alzheimer’s therapy.
More changes ahead for Takeda with new CEO set to take reins
Takeda’s multi-year restructuring will continue under incoming CEO Julie Kim. The company announced Wednesday that the board has approved “next steps” in its transformation that will put the focus on upcoming launches and its late-stage …
How Seaport is hedging against failure in Phase 2b depression study
Seaport Therapeutics is building a fail-safe into its Phase 2b depression trial. The biotech is testing its drug, called SPT-300, in patients with major depressive disorder. But executives believe SPT-300 could prove more promising in …
FDA approves Corcept’s Lifyorli for ovarian cancer months early
The FDA approved Corcept Therapeutics’ Lifyorli in combination with nab-paclitaxel for the treatment of three different kinds of cancer in patients who have received up to three prior lines of treatments. The Wednesday approval came …
ImmunityBio warned by FDA over ‘misleading’ Anktiva content
The FDA has sent a warning letter to ImmunityBio over “false and misleading” comments made by executive chair, billionaire Patrick Soon-Shiong.